Potassium Ion

Potassium Ion

SCHEMBL4885554

O=C([O-])[C@H]1O[C@@H]1c1ccccc1.[K+]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 8/20 0.60
TSHR P16473 1/20 0.51
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
EDNRA P25101 1/20 0.35
HDAC4 P56524 3/20 0.35
CAPN1 P07384 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL9487151 1.00 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
Potassium Ion SCHEMBL6580827 1.00 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
Potassium Ion SCHEMBL9487155 1.00 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
SCHEMBL6027430 0.96 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
Lithium Ion SCHEMBL10477590 0.96 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
SCHEMBL9459180 0.96 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
Potassium Ion SCHEMBL28558054 0.82 EPHX1 (0.60) EPHX1TSHRMEN1TP53CYP1A2
Potassium Ion SCHEMBL28556849 0.82 EPHX1 (0.42) EPHX1TSHRMEN1TP53CYP1A2
SCHEMBL15307543 0.80 EPHX1 (0.67) EPHX1TSHRMEN1TP53CYP1A2
SCHEMBL9458781 0.80 EPHX1 (0.67) EPHX1TSHRMEN1TP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249310-A1 Process For the Preparation of (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionamide and (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionic Acid Alkyl Ester DSM IP ASSETS B.V. (NL) 2008-10-09 US disclosed
EP-1831150-A1 PROCESS FOR THE PREPARATION OF (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONAMIDE AND (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONIC ACID ALKYL ESTER DSMIP Assets B.V. (NL) 2007-09-12 EP disclosed
WO-2006008170-A1 PROCESS FOR THE PREPARATION OF (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONAMIDE AND (2R, 3R)-2-HYDROXY-3-AMINO-3-ARYL-PROPIONIC ACID ALKYL ESTER DSM IP ASSETS B.V. (NL) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249310-A1 Process For the Preparation of (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionamide and (2R,3R)-2-Hydroxy-3-Amino-3-Aryl-Propionic Acid Alkyl Ester GRHPR, B3GAT3, HCAR3 EPHX1 1266/4885TSHR 335/4885MEN1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.